Friday, May 9, 2008, 9:58PM ET - U.S. Markets Closed.
- Home
- Tech Industries
- Topics
- Reporters
- Subscribe
Healthcare Information
Barron's Wyeth Story All Pro; Here's the Con
Apr 07, 2008 03:45pm EDT by Aaron Task in Biotech and Clean Tech, Healthcare Information
Shares of Wyeth and Elan were big winners Monday thanks to a Barron's article about the potential of bapineuzumab, a treatment for Alzheimer's disease being codeveloped by the firm.
But the Barron's story omits many key items, says Adam Feuerstein, senior writer at TheStreet.com. Feuerstein's own coverage has revealed that an oft-cited paper touting the promise of bapineuzumab was written by authors who are paid consultants to Wyeth and Elan.
Feuerstein further notes the drugmakers also developed the test cited in the paper, suggesting a level of control (and conflict) that is not being reflected in the rush to buy the stocks.
» More
Most Recommended
Blogroll
Market Movers
Most Active
More Market Movers
Top Tech Stories
- Former Siemens chief faces admin probeat FT.com (Fri 9:25pm)
- XP and Vista: A Look at the Numbersat The Wall Street Journal Online (Fri 8:57pm)
- Scientific Games Corp. Q1 2008 Earnings Call Transcriptat Seeking Alpha (Fri 8:55pm)
- GeoEye Inc. Q1 2008 Earnings Call Transcriptat Seeking Alpha (Fri 8:51pm)
Yahoo! Finance Videos
Copyright/IP Policy - Terms of Service - Privacy Policy - Help
Quotes delayed, except where indicated otherwise. Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.
Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. Fundamental company data provided by Capital IQ. Financials data provided by Edgar Online. Dividend data provided by Hemscott Americas. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data and daily updates provided by Hemscott Americas. Fund summary, fund performance and Morningstar Index data provided by Morningstar. Analyst estimates data provided by Thomson Financial Network. All data provided by Thomson Financial Network is based solely upon research information provided by third party analysts. Yahoo! has not reviewed, and in no way endorses the validity of such data. Yahoo! and ThomsonFN shall not be liable for any actions taken in reliance thereon. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.